接骨七厘胶囊

Search documents
这家A股公司,被证监会立案调查!
证券时报· 2025-05-28 14:26
Core Viewpoint - The company, Jiaying Pharmaceutical, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact its operations and reputation [1]. Group 1: Company Overview - Jiaying Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine, holding a significant position in the industry with 58 drug varieties across 5 dosage forms [3]. - The company's leading products, Shuangliao Houfeng San and Zhonggan Ling Pian, have been recognized as national protected traditional Chinese medicine varieties and have won the "Guangdong Province Famous Brand Product" title [3]. - Jiaying Pharmaceutical's subsidiary, Jiaying Hunan, produces unique products listed in the national medical insurance directory, including Jieguzhi Qili Pian and Jieguzhi Qili Jiao Nang, both of which have patent authorization [3]. Group 2: Financial Performance - In 2024, Jiaying Pharmaceutical reported total revenue of 376 million yuan, a year-on-year decline of 29.46%, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% [3]. - Despite the financial challenges, the company has implemented measures such as optimizing production processes and enhancing cost control to maintain stable core business operations [3]. - In Q1 2025, Jiaying Pharmaceutical achieved revenue of 122 million yuan, a year-on-year increase of 28.83%, primarily due to expanded sales channels [3]. - The net profit attributable to shareholders for the same period was 15.40 million yuan, reflecting a significant year-on-year growth of 197.23%, driven by successful partnerships with major retail chains and improved cost management [3]. Group 3: Corporate Governance - During a recent earnings briefing, the company addressed investor concerns regarding its governance, stating that the current Secretary of the Board was recruited from a state-owned enterprise, emphasizing high compliance management standards [4]. - The company has undertaken substantial efforts in compliance and internal control, including appointing dedicated compliance personnel and implementing electronic process management [4]. - Future plans include enhancing compliance systems and culture, ensuring business operations and information disclosures are compliant and scientifically managed [4].
行业背景股东加持 嘉应制药经营业绩连续两季度增长
Zheng Quan Ri Bao Wang· 2025-04-27 11:43
嘉应制药相关人士向《证券日报》记者表示,尽管2024年业绩依然承压,但在养天和大药房股份有限公 司(以下简称"养天和")入股和公司董事、监事、高级管理人员等换届选举之后,嘉应制药经营业绩明 显向好。 "嘉应牌"荣获广东省老字号 本报讯 (记者丁蓉 见习记者张美娜)4月26日,广东嘉应制药(002198)股份有限公司(以下简称"嘉 应制药")披露2024年年度报告。报告期内,公司实现营业收入3.76亿元,同比下降29.46%;归母净利 润2061.16万元,同比下降39.94%。 然而,嘉应制药同日披露的2025年一季度报告显示,公司一季度营业收入为1.22亿元,同比增长 28.83%;归母净利润1540.33万元,大幅增长197.23%。 2024年,面对医药行业政策调整深化、市场竞争加剧、原材料价格波动等多重挑战,嘉应制药通过优化 生产流程、强化成本管控、开拓新兴市场等措施,确保了核心业务的稳定运行。 年报显示,嘉应制药现拥有5个剂型、70多个药品品种,主要产品如料喉风散、重感灵片等曾为国家中 药保护品种,且均荣获"广东省名牌产品"称号,具有良好的知名度;接骨七厘片、接骨七厘胶囊为独家 生产的全国医保目录产 ...
一季度盈利增两倍,嘉应制药经营业绩大幅向好
Zheng Quan Zhi Xing· 2025-04-26 01:35
Core Viewpoint - Despite facing challenges in 2024, such as policy adjustments and market competition, the company has shown significant improvement in its operational performance following the acquisition by Yangtianhe and the restructuring of its board and management team [1][7]. Financial Performance - In 2024, the company reported a revenue of 376 million yuan, a decrease of 29.46% year-on-year, and a net profit attributable to shareholders of 20.61 million yuan, down 39.94% year-on-year [1][6]. - The first quarter of 2025 showed a revenue of 122 million yuan, an increase of 28.83% year-on-year, and a net profit of 15.40 million yuan, a substantial increase of 197.23% [1][10]. Product and Market Development - The company has launched new products such as the Solid Essence Ginseng and Deer Antler Pills, which have quickly gained sales momentum [4]. - The company’s traditional Chinese medicine products are well-known, with leading products recognized as national protected varieties and awarded the title of "Guangdong Province Famous Brand Products" [3]. Strategic Changes - In July 2024, Yangtianhe acquired a 7% stake in the company, becoming the second-largest shareholder, which is expected to enhance resource allocation and collaboration [8]. - Following the acquisition, the company underwent a board and management restructuring, with Yangtianhe's chairman taking the role of the new chairman, bringing in industry professionals to explore new market opportunities [8][9]. Future Outlook - The company plans to stabilize production capacity, optimize its supply system, expand market share through multi-channel strategies, and enhance core competitiveness through technology in 2025 [10].